Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a randomized double-blind placebo-controlled multicenter study of CM-101 in adults with nonalcoholic steatohepatitis
MOH_2020-03-30_008503Phase 2Not yet recruiting
- Sponsor
- Chemomab Therapeutics
- Start
- Dec 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in metabolic dysfunction-associated steatohepatitis (MASH) comparing CM-101 with Placebo (2 arms). Primary endpoint: Safety and tolerability of repeated subcutaneous CM-101. Planned start Dec 2019; status: not yet recruiting.
02
Drugs
nebokitug
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on MOH_2020-03-30_008503.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-03-30_008503.